177Lu-DOTATATE Uptake in the Lungs of a Patient With COVID-19 Pneumonia.

Abstract

A 76-year-old woman with liver and bone metastasis of a duodenal neuroendocrine tumor received peptide receptor radionuclide therapy with 177Lu-DOTATATE. Scintigraphy with SPECT/CT performed 4 days after the treatment demonstrated 177Lu-DOTATATE uptake as multifocal ground glass opacities in the bilateral lungs. This uptake was considered to be due to COVID-19 pneumonia because the patient was infected with the virus 7 days prior to the treatment. The lung opacities became smaller, showing a decreased uptake, 2 months later, after the second treatment. 177Lu-DOTATATE may be taken up during the active phase of COVID-19 pneumonia.